Analyst Downgrades Qualcomm: 'Share Appreciation Hinges On Licensing Resolutions'

QUALCOMM, Inc. (NASDAQ: QCOM) is facing multiple headwinds, according to an analyst at Bank of America Merrill Lynch.

The Analysts

Tal Liani downgraded Qualcomm from Buy to Neutral and reduced his price target from $75 to $70.

The Thesis

Qualcomm's management has used up most opportunities for P&L restructuring, Liani said in a note. Even after this, earnings upside alone can't lead to share price appreciation, and the company has to resolve its ongoing licensing disputes with Huawei and Apple Inc. (NASDAQ: AAPL), he added.

The catch here is the timing of the dispute redressal is uncertain.

Liani said Qualcomm could also be constrained by softening smartphone demand, and accordingly lowered his estimates.

The analyst thinks the company's FY19 EPS guidance of $5.25 doesn't seem achievable. Liani's revised EPS estimate of $4.21 is 6 percent below the consensus.

Additionally, BofA doesn't see 5G as a major driver in the foreseeable future, as meaningful device shipments could commence only in 12-18 months. That said, the firm sees near-term support emerging from the company's $16 billion accelerated share repurchase program.

"Share price support is a positive in the near term, but also a negative factor, as past experience indicates that associated stability can reverse after buyback programs end," Liani said.

Price Action

At time of writing, Qualcomm shares traded around $63.37.

Related Links:

No Qualcomm? No Problem: NXP Semiconductors Is Still A 'King'

Qualcomm's Risk-Reward Is Too Favorable to Ignore, Cowen Says In Upgrade

Photo courtesy of Qualcomm.

Latest Ratings for QCOM

Oct 2018	Bank of America	Downgrades	Buy	Neutral
Sep 2018	Stifel Nicolaus	Maintains	Hold	Hold
Sep 2018	Canaccord Genuity	Maintains	Buy	Buy

View More Analyst Ratings for QCOM
View the Latest Analyst Ratings

See more from Benzinga

• Apple Q4 Earnings Preview: New iPhones, China, Services And More

• Analysts Stay Bullish On iQiyi After Q3 Print, But Investors Unhappy With Lower Ad Revenue

• The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.